On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
After the second quarter, Supernus Pharmaceuticals reported net cash, cash equivalents, and marketable securities of $677.7 million compared to $273.7 million on December 31, 2017.
On September 6, the U.S. Court of Appeals for the Federal Circuit confirmed the New Jersey District Court’s decision that TWi infringed three Oxtellar XR Orange Book patents held by Supernus Pharmaceuticals. The court also confirmed that all three Oxtellar XR patents in the Orange Book are valid. Oxtellar XR has eight patent protections, none of which are set to expire before 2027.
Of the nine analysts tracking Supernus Pharmaceuticals (SUPN) stock in September, three recommended a “strong buy” while five analysts recommended a “buy” rating. One analyst recommended a “hold” for Supernus Pharmaceuticals.
On September 11, Supernus Pharmaceuticals had a consensus 12-month target price of $60.22, which represents an ~23.4% ROI (return on investment) over the next 12 months.
All 13 analysts tracking Neurocrine Biosciences (NBIX) in September recommended a “buy” for its stock. Likewise, all 12 analysts tracking Adamas Pharmaceuticals (ADMS) recommended a “buy” for its stock. All 11 analysts tracking Heron Therapeutics (HRTX) in September recommended a “buy.”
On September 11, Neurocrine Biosciences, Heron Therapeutics, and Adamas Pharmaceuticals had consensus 12-month target prices of $134.08, $51.73, and $54.00, respectively, which represents ~10.05%, ~36.31%, and ~139.68% ROI over the next 12 months.